School of Medicine
Showing 1-25 of 25 Results
-
Jeffrey A. Feinstein, MD, MPH
Dunlevie Family Professor of Pulmonary Vascular Disease and Professor, by courtesy, of Bioengineering
Current Research and Scholarly InterestsResearch interests include (1) computer simulation and modeling of cardiovascular physiology with specific attention paid to congenital heart disease and its treatment, (2) the evaluation and treatment of pulmonary hypertension/pulmonary vascular diseases, and (3) development and testing of medical devices/therapies for the treatment of congenital heart disease and pulmonary vascular diseases.
-
Heidi M. Feldman
Ballinger-Swindells Endowed Professor of Developmental and Behavioral Pediatrics
Current Research and Scholarly InterestsMy current research program focuses on infants born preterm, before 32 weeks gestation from two language environments: English and Spanish. The study considers how neurobiological factors, specifically properties of the white matter circuits in the brain, interact with social, psychological, and economic factors to predict language processing efficiency at 18 months of age.
-
Nielsen Fernandez-Becker
Clinical Professor, Medicine - Gastroenterology & Hepatology
BioI am the director of the Celiac Disease Program at Stanford and I am highly experienced in diagnosis and management of celiac disease and gluten associated disorders.
My objective is to provide excellent and compassionate clinical care for my patients while seeking a better understanding of diseases I treat, particularly Celiac disease (CeD), eosinophilic esophagitis (EoE). My top priorities are patient care and translational research to make new discoveries and improve the care my patients. -
Michael Fischbach
Liu (Liao) Family Professor
Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.
1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.
2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:
Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?
Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?
3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing. -
Paul Graham Fisher, MD
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
On Partial Leave from 07/15/2024 To 07/13/2025Current Research and Scholarly InterestsClinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors and other cancers in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies.
-
Philip Andrew Fisher
Diana Chen Professor of Early Childhood Learning and Professor, by courtesy, of Pediatrics
BioDr. Philip Fisher is the Diana Chen Professor of Early Childhood Learning in the Graduate School of Education at Stanford. His research, which has been continuously funded by the National Institutes of Health since 1999, focuses on developing and evaluating scalable early childhood interventions in communities, and on translating scientific knowledge regarding healthy development under conditions of adversity for use in social policy and programs. He is particularly interested in the effects of early stressful experiences on children's neurobiological and psychological development, and in prevention and treatment programs for improving children's functioning in areas such as relationships with caregivers and peers, social-emotional development, and academic achievement. He is currently the lead investigator in the ongoing RAPID-EC project, a national survey on the well-being of households with young children during the COVID-19 pandemic. Dr. Fisher is also interested in the brain's plasticity in the context of therapeutic interventions. He is the developer of a number of widely implemented evidence-based interventions for supporting healthy child development in the context of social and economic adversity, including Treatment Foster Care Oregon for Preschoolers (TFCO-P), Kids in Transition to School (KITS), and Filming Interactions to Nurture Development (FIND). He has published over 200 scientific papers in peer reviewed journals. He is the recipient of the 2012 Society for Prevention Research Translational Science Award, and a 2019 Fellow of the American Psychological Society.
-
Barry Fleisher
Associate Professor of Pediatrics at the Lucile Salter Packard Children's Hospital, Emeritus
Current Research and Scholarly InterestsNeonatology, neurobehavioral development, outcomes in premature infants.
-
Eric Foote
Clinical Assistant Professor, Pediatrics - Neonatal and Developmental Medicine
BioEric Foote is a pediatric hospitalist with experience conducting clinical and public health research around the world. His research focuses on identifying and intervening on health disparities in low income countries and in low resource settings. Currently, he is developing and evaluating a community health worker-led household phototherapy intervention to extend access to neonatal jaundice care for newborns in rural Bangladesh. He is also working to improve SARS-CoV-2 testing and genomic surveillance across California and worldwide.
-
James Ford
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsMammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.
-
Uta Francke
Professor of Genetics and of Pediatrics, Emerita
Current Research and Scholarly InterestsFunctional consequences and pathogenetic mechanisms of mutations and microdeletions in human neurogenetic syndromes and mouse models. Integration of genomic information into medical care.
-
Jennifer Frankovich
Clinical Professor, Pediatrics - Rheumatology
Current Research and Scholarly InterestsMy primary interest and role at Stanford is to evaluate and treat children with both systemic and organ specific autoimmune disease. In October of 2012, we started a multidisciplinary clinic dedicated to treating patients with PANS (Pediatric Acute-onset Neuropsychiatric Syndromes). I am currently the clinical and research director for the PANS program.
-
Adam Frymoyer
Clinical Professor, Pediatrics - Neonatal and Developmental Medicine
Current Research and Scholarly InterestsMy research interests focus on understanding the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of medicines used in complex pediatric populations. This includes identifying sources of variation in drug response through the application of population PK-PD modeling and simulation approaches. The goal is to ultimately apply this quantitative understanding to guide therapeutic decision-making in infants and children.
-
Janene Fuerch
Clinical Associate Professor, Pediatrics - Neonatal and Developmental Medicine
BioJanene H. Fuerch, MD is a Clinical Associate Professor of Neonatology at Stanford University Medical Center, as well as an innovator, educator, researcher and physician entrepreneur. She has an undergraduate degree in Neuroscience from Brown University and a medical degree from the Jacobs School of Medicine at SUNY Buffalo. At Stanford University she completed a pediatrics residency, neonatal-perinatal medicine fellowship and the Byers Center for Biodesign Innovation Fellowship.
She is also Assistant Director of the Biodesign Innovation Fellowship Program at Stanford University, and Co-Director of Impact1 where she mentors and advises new entrepreneurs through all aspects of medical device development, from identifying clinical needs to commercialization. Her specific areas of investigational interest include the development and commercialization process of neonatal, pediatric and maternal health medical devices as well as the utilization of a simulated environment to develop and test medical devices. She is a national leader in neonatal resuscitation, ECMO, device development and has been an AHRQ and FDA funded investigator. But her work extends outside of the academic realm to industry having co-founded EMME (acquired by Simple Health 2022) an award-winning reproductive health company, medical director for Novonate (acquired by Laborie 2023) a neonatal umbilical catheter securement company and notable consultant for Vitara (EXTEND - artificial environment to decrease complications of prematurity), and Avanos™. Janene is passionate about improving the health of children and newborns through medical device innovation and research.
